Smoking Cessation Intervention for Diabetic Patients

糖尿病患者的戒烟干预

• 批准号: 8191089
• 负责人: Susan E Ramsey
• 金额: $ 35.64万
• 依托单位: RHODE ISLAND HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-09-15 至 2013-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8191089
• 关键词: Abstinence; Adaptive Behaviors; Address; Affect; Affective; Area; Behavior; Behavior Therapy; Behavioral; Clinical; Clinical Trials; Cognitive; Combination Medication; Combined Modality Therapy; Development; Diabetes Mellitus; Elements; Emotional; Feedback; Future; General Population; Health; Individual; Intervention; Knowledge; Life; Manuals; Measures; Mediating; Mental Depression; Modeling; Morbidity - disease rate; National Institute of Drug Abuse; Nicotine Withdrawal; Non-Insulin-Dependent Diabetes Mellitus; Outcome; Patients; Perception; Pharmacotherapy; Phase; Population; Prevalence; Protocols documentation; Randomized; Randomized Controlled Trials; Recommendation; Recruitment Activity; Relapse; Relative (related person); Reporting; Research; Risk; Sampling; Smoke; Smoker; Smoking; Smoking Cessation Intervention; Specific qualifier value; Staging; Testing; Time; Training; Treatment Efficacy; Withholding Treatment; Work; base; coping; depressive symptoms; diabetic patient; distress tolerance; experience; improved; innovation; meetings; mortality; nicotine patch; nicotine replacement; novel; phase 1 study; phase 2 study; population health; programs; randomized trial; skills; smoking cessation; smoking relapse; successful intervention; therapy development; trial comparing

DESCRIPTION (provided by applicant): Individuals with Type 2 diabetes smoke at rates similar to those found in the general population, and the health consequences of smoking are particularly severe among smokers with diabetes. In fact, there appears to be a synergistic effect between smoking and diabetes on mortality. However, despite reports that highlight the importance of this work, a paucity of studies have been conducted to develop and test smoking cessation interventions tailored to meet the needs of individuals with diabetes. The small number of extant studies have yielded mixed results. Distress tolerance (DT) focused, acceptance-based interventions have demonstrated efficacy for smoking cessation, and there is increasing support for the conceptual model underlying these interventions among individuals with diabetes. The long-term objective of this research program is to improve smoking cessation treatment for individuals with Type 2 diabetes by developing and establishing the efficacy of a DT smoking cessation intervention tailored to this population. Furthermore, we seek to advance knowledge of the relationships among nicotine withdrawal, negative affect, distress tolerance, and smoking cessation outcomes among individuals with diabetes. In the present application, we propose to develop a DT intervention tailored to meet the needs of smokers with Type 2 diabetes. In the first phase of this project, we will develop and pilot the intervention with 18 patients. In the second phase of the project, we will conduct a preliminary, randomized trial with 54 patients to examine the efficacy of the DT intervention relative to a standard smoking cessation treatment (ST) that equates for therapist contact time. Patients in both conditions will receive the transdermal nicotine patch. We expect that, relative to the ST condition, patients randomized to the DT condition will have increased likelihood of smoking abstinence and increased latency to both smoking lapse and relapse. If the efficacy of this intervention can be established in this trial and in subsequent large scale randomized controlled trials, smokers with diabetes will have improved smoking cessation treatment options. The need for this work is great given the paucity of extant work in this area, the significantly heightened risk of morbidity and mortality from smoking among diabetic patients, the rapidly increasing rate of diabetes in the U.S., and an apparent stabilization of the smoking rate in recent years. PUBLIC HEALTH RELEVANCE: The proposed study aims to develop and test a smoking cessation intervention for smokers with Type 2 diabetes. This is an important population on which to focus given the increased risk of negative health effects from smoking among individuals with diabetes. If successful, this intervention could help individuals with diabetes to successfully quit smoking and to live longer, healthier lives.

描述（由申请人提供）：2型糖尿病的人以类似于普通人群中的糖尿病烟雾，而吸烟的健康后果在糖尿病的吸烟者中尤为严重。实际上，吸烟和糖尿病对死亡率之间似乎有协同作用。然而，尽管有报道称这项工作的重要性，但仍进行了大量研究，以开发和测试量身定制的戒烟干预措施，以满足糖尿病患者的需求。现存的少量研究产生了混合的结果。遇险耐受性（DT）以验收为基础的干预措施已证明了戒烟的功效，并且对糖尿病患者中这些干预措施的概念模型的支持越来越大。该研究计划的长期目标是通过开发和确定针对该人群量身定制的DT戒烟干预措施的功效来改善2型糖尿病患者的戒烟治疗。此外，我们试图提高人们对尼古丁戒断，负面影响，忍受宽容和戒烟结果之间的关系的了解。在本应用中，我们建议开发针对2型糖尿病吸烟者的需求而定制的DT干预措施。在该项目的第一阶段，我们将与18名患者开发并试行干预措施。在项目的第二阶段，我们将对54名患者进行初步的随机试验，以检查DT干预相对于标准的吸烟戒烟治疗（ST）的功效，该疗效等同于治疗师的接触时间。在这两种情况下的患者都将接受透皮尼古丁斑块。我们希望，相对于ST条件，随机分配到DT条件的患者将增加戒烟的可能性，并增加了吸烟和复发的潜伏期。如果可以在此试验中建立这种干预措施的功效，并且在随后的大规模随机对照试验中，糖尿病的吸烟者将改善戒烟治疗方案。考虑到该领域现有工作的缺乏，对这项工作的需求很大，糖尿病患者吸烟的发病率和死亡风险显着提高，近年来美国糖尿病速度迅速增加，吸烟率明显稳定。 公共卫生相关性：拟议的研究旨在为2型糖尿病的吸烟者开发和测试戒烟干预措施。鉴于糖尿病患者吸烟会增加健康影响的风险增加，这是一个重要的人群。如果成功的话，这种干预措施可以帮助糖尿病患者成功戒烟，并生活更长，更健康。